30 closest matches · ranked by relevance
Congenital Cytomegalovirus Infection · Maternal Cytomegalovirus Infection
Primary: Number of Participants With the Composite Primary Outcome — 46; 37 Participants — p=0.42
Cytomegalovirus Infection
Primary: Incidence of Cytomegalovirus (CMV) Disease. — 9; 20 participants — p=0.0396
Cytomegalovirus Disease
Primary: Number of Patients With Late CMV Disease — 0; 0 Participants
CMV
Primary: Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant — 155; 78 Participants
Transplant Complication · CMV
Primary: Clinical Significant Leukopenia — 8; 1 Participants
Cytomegalovirus Infection
Primary: Number of Participants With Clinically Significant CMV Infection — 13; 4; 6; 4 Participants
CMV DNAemia Pre-engraftment
Primary: Time to Engraftment (Days) Stratified by CMV DNaemia Occurring Before or After Neutrophil's Engraftment — 17; 19 days
Cytomegalovirus Infections
Primary: Percentage of Participants With Active Cytomegalovirus (CMV) Infection Within 12 Months — 14.1; 42.6 percentage of participants
Cytomegalovirus Infections
Primary: Number of Participants With Endpoint Committee (EC)-Confirmed Cytomegalovirus (CMV) Disease Within 6 Months Post-Transplantation — 11; 20 participants — p=0.789
CMV · CMV Infection · Hematopoietic Cell Transplant
Primary: Clinically Significant CMV Viremia for Hematopoietic Cell Transplantation/HCT Participants in the Interventional Cohort Only — 5; 0; 31; 0 Participants
Cytomegalovirus Infections
Primary: Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease up to Month 12 Post-transplant — 43.6; 23.9 Percentage of patients — p=<=0.0002
Cytomegalovirus
Primary: Number of Participants With a Complete Response — 8; 50 Participants
Prevention of CMV Infection or Disease
Primary: Percentage of Participants With Clinically-significant CMV Infection up to Week 24 Post-transplant — 37.5; 60.6 Percentage of participants — p=<0.0001
EBV Viremia · CMV Viremia
Primary: Incidence of EBV or CMV Related Disease in Transplant Recipient — 2; 0 participants
Acute Lung Injury · Acute Respiratory Distress Syndrome · Respiratory Failure
Primary: Serum IL-6 Level — -0.79; -0.79 pg/mL
Cytomegalovirus Infections
Primary: Number of Participants With Endpoint Committee (EC)-Confirmed Cytomegalovirus (CMV) Disease Within 6 Months Post-Transplantation — 14; 10 number of participants with…
Cytomegalovirus Infections
Primary: Incidence of CMV End Organ Disease — 21; 1 participants
Transplantation Infection · Epstein-Barr Virus Infections · Cytomegalovirus Infections
Primary: Compare Incidence, Duration and Magnitude of CMV and EBV Viremia in Kidney Transplant Recipients Receiving valA vs. valG. — 16; 20; 8; 4 Participants
Cytomegalovirus Infection
Primary: Change in Best Ear Hearing Assessments at 6 Months. — 3; 5; 37; 36 participants
CMV Disease
Primary: Percentage of Participants With Adjudicated Cytomegalovirus (CMV) Disease Through 52 Weeks Post-transplant — 10.4; 11.8 Percentage of Participants
Cytomegalovirus Disease · Cytomegalovirus Infections · Heart Transplant Infection
Primary: Proportion of Patients With Neutropenia Compared to Historical Controls — 0; 30 Participants — p=0.02
Infections, Cytomegalovirus · Cytomegalovirus Infections
Primary: Number of Subjects With Any Cytomegalovirus (CMV) Congenital Infection — 24; 20; 4; 58 Participants
Cytomegalovirus Infection · Cytomegalovirus Disease
Primary: Percentage of Participants With Adverse Events (AEs) — 90.9 Percentage of Participants
B-Cell Prolymphocytic Leukemia · Chronic Lymphocytic Leukemia · Peripheral T-Cell Lymphoma
Primary: Cytomegalovirus (CMV) Reactivation
Cytomegalovirus Disease
Primary: Incidence of CMV Disease or CMV Viremia — 29; 9; 26 Participants
Cytomegalovirus Infection
Primary: Number of Ears That Had (1) Improved Hearing or no Change in Hearing (2) Worsened Hearing. — 27; 20; 1; 6 Ears — p=0.0859
CMV Infection · Persistent CMV Viremia
Primary: Complete Response — 20; 57 Participants
Cytomegalovirus Infections
Primary: Virological Response on Treatment Week 6 — 5 Participants
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable · Leukemia · Lymphoma
Primary: Number of Participants With Adverse Events — 1; 31; 1; 22 Participants
Cytomegalovirus (CMV)
Primary: Number of Participants With Confirmed Undetectable Plasma Cytomegalovirus (CMV) Within 6 Weeks — 28; 25; 27 participants